Home › NDC Lookup › Ingredients › Pyridostigmine Bromide › 72205-0098-72
Pyridostigmine Bromide 60 mg/5mL Solution, 473 mL Bottle — NDC 72205-0098-72 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

NDC 72205-0098-72: Pyridostigmine Bromide 60 mg/5mL Solution, 473 mL Bottle

by Novadoz Pharmaceuticals LLC

This is a package of 473 mL of Pyridostigmine Bromide 60 mg/5mL Solution from Novadoz Pharmaceuticals LLC, first listed with the FDA Sep 2023 and currently FDA-listed; retail pharmacies pay about $0.7131 per mL (NADAC). It is this product's only package size.

🏷️ FDA NDC (as labeled) 72205-098-72 billing pads the product segment with a zero
Rx only Generic FDA-listed Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Nov 21, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 72205-098-72 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
72205 labeler · 098 product · 72 package
Package marketed since
Sep 26, 2023
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
473 mL per package
Barcode (UPC)
0372205098725
Medicaid fills, this package
871 prescriptions in the last four reported quarters
FDA record last changed
Nov 21, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 72205-098-72
Product NDC 72205-098
11-digit billing NDC 72205009872
NCPDP billing unit ML — per mL (volume)
RxCUI 903843
UNII KVI301NA53
UPC 0372205098725
Application # ANDA216512
SPL Set ID 0bed477f-b228-4f8d-a956-f192b1329ea0
Established class (EPC) Cholinesterase Inhibitor
Mechanism of action Cholinesterase Inhibitors
DEA schedule Non-controlled
Marketing category ANDA
Marketing status FDA-listed
FDA listing status Listed (active directory)
Marketing start 2023-09-21
Route ORAL
Dosage form SOLUTION
Substance PYRIDOSTIGMINE BROMIDE
TE code (Orange Book) AA · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 76000050102060
GCN Seq No 004763
GCN 18520
HICL code 001990
Ingredient (HICL) Pyridostigmine Bromide
HIC1 code J
Therapeutic class — broad (HIC1) Autonomic Nervous System
HIC2 code J1
Therapeutic class — intermediate (HIC2) Cholinergics
HIC3 code J1B
Therapeutic class — specific (HIC3) Cholinesterase Inhibitors
AHFS code 12:04.00.00
AHFS class Parasympathomimetic (Cholinergic Agents)
FDB label name PYRIDOSTIGMINE 60 MG/5 ML SOLN
FDB brand name Pyridostigmine Bromide
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 004763
  • GCN: 18520
  • GPI-14 (Medi-Span): 76000050102060
  • HICL (First Databank): 001990
  • AHFS class code: 12:04.00.00
  • RxCUI (RxNorm): 903843
Why two NDCs? The FDA registers this code as 72205-098-72 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 72205-0098-72. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Cholinesterase Inhibitor class.

Pharmacologic class Cholinesterase Inhibitor
Drug family (ATC) Anticholinesterases
How it works Cholinesterase Inhibitors
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name PYRIDOSTIGMINE 60 MG/5 ML SOLN Ingredient Pyridostigmine Bromide
📖 What it is MedlinePlus · NLM

Pyridostigmine is used to treat myasthenia gravis. Pyridostigmine is in a class called cholinergic agents. It works by increasing the amount of certain natural substances in the body to improve nerve and muscle activity.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It depends on the product. Mestinon and other oral forms treat myasthenia gravis. Regonol injection reverses muscle relaxants after surgery. A military-only version is for soman ne...
  • For myasthenia gravis products, follow your prescriber and label. The military-only extended-release tablet must be taken with a medium-fat or high-fat meal, not on an empty stomac...
  • Stomach upset such as diarrhea, cramps and nausea is most common. Muscle twitching, sweating and extra saliva can also happen. Call your doctor if they bother you.
  • Get help right away for trouble breathing, severe dizziness, fainting, or increasing muscle weakness. These can be signs of a serious reaction or too much medicine.
📖 Read our full Pyridostigmine guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.713 $337.30 / 473 ml
Medicaid paysCMS SDUD · 12 mo $0.9104 $430.62 / 473 ml
Medicare drug plans payPart D · Q2 2026 $1.24 $587.28 / 473 ml
NADAC price history (per mL) — tap or hover for the price & month
Jan 2025 Aug 2025 Mar 2026 Nov 2026 $1.006 $0.457
▼ Down 29% over the last 23 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
72205-0098-72 You're viewing this Main listing 473 mL in 1 BOTTLE 2023-09-26 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Pryidostigmine Bromide 60 mg/5mL 16571-0833-16 Rising 473 ml $0.713 AA Availability likely —
Pyridostigmine Bromide 60 mg/5mL 42192-0626-16 Acella 473 ml $0.713 AA Availability likely —
Pyridostigmine Bromide 60 mg/5mL 69238-1731-02 Amneal 473 ml $0.713 AA Availability likely —
Pyridostigmine 60 mg/5mL 70954-0148-10 Novitium 473 ml $0.713 AA Availability likely —
Pyridostigmine Bromide 60 mg/5mLthis 72205-0098-72 Novadoz 473 ml $0.713 AA Availability likely —
pyridostigmine bromide 60 mg/5mL 68682-0307-05 Oceanside 473 ml $0.842 AA Discontinued +18%
Mestinon 60 mg/5mL 00187-3012-20 Bausch 473 ml — AA FDA listed —
Pryidostigmine Bromide 60 mg/5mL 24689-0104-01 Apnar 473 ml — AA FDA listed —
Pyridostigmine Bromide 60 mg/5mL 66689-0406-10 VistaPharm, 10 cups — AA FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2023
Listed with the FDA since
Sep 2023
📍
2026
Currently FDA-listed
3 years listed
🔓
·
This is a generic
listed with the FDA
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

FlavorRaspberry
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Pyridostigmine inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 3K9958V90M
    A liquid solvent derived from fermentation or chemical synthesis. In medicines, alcohol dissolves active ingredients, helps preserve the product, and improves how the body absorbs certain drugs.
  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII 33X04XA5AT
    Lactic acid is a naturally occurring organic acid derived from milk or plant sources. It lowers and maintains pH in formulations, helps preserve the product, and can enhance ingredient stability and absorption.
  • UNII OJ245FE5EU
    Sodium benzoate is a salt derived from benzoic acid, a preservative. It's added to medicines to prevent growth of bacteria, fungi, and other microorganisms that could spoil the product.
  • UNII 506T60A25R
    Sorbitol is a natural sugar alcohol derived from glucose. It serves as a sweetener, humectant, and bulking agent in medications to improve taste and help maintain moisture in the product.
  • UNII C151H8M554
    A natural sugar derived from sugar cane or sugar beets. It's used as a sweetener, filler, and binder to improve taste, add bulk, and help hold tablet or capsule ingredients together.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

7 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerNovadoz Pharmaceuticals LLC
Application holderMSN LABORATORIES PRIVATE LTD
FDA applicationANDA216512 (ANDA)
Labeler code72205
First marketedSep 2023
Product typeHuman Prescription Drug
Portfolio249 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 13 words ▾

INDICATION: Pyridostigmine bromide oral solution is useful in the treatment of myasthenia gravis.

⏱️ Dosage and Administration 149 words ▾

DOSAGE AND ADMINISTRATION: Pyridostigmine Bromide Oral Solution, USP is available in following form: Oral Solution - raspberry-flavored, containing 60 mg pyridostigmine bromide per teaspoonful (5 mL). This form permits accurate dosage adjustment for children and “brittle” myasthenic patients who require fractions of 60 mg doses. It is more easily swallowed, especially in the morning, by patients with bulbar involvement.

Dosage: The size and frequency of the dosage must be adjusted to the needs of the individual patient. Oral Solution: The average dose is ten 5 mL teaspoonfuls daily, spaced to provide maximum relief when maximum strength is needed. In severe cases as many as 25 teaspoonfuls a day may be required, while in mild cases one to six teaspoonfuls a day may suffice.

NOTE: For information on a diagnostic test for myasthenia gravis, and for the evaluation and stabilization of therapy, please see product literature on Tensilon (edrophonium chloride).

⛔ Contraindications 41 words ▾

CONTRAINDICATIONS: Pyridostigmine bromide is contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial asthma. Care should be observed in the use of atropine for counteracting side effects, as discussed below.

⚠️ Warnings ~1 min read ▾

WARNINGS: Although failure of patients to show clinical improvement may reflect underdosage, it can also be indicative of overdosage. As is true of all cholinergic drugs, overdosage of pyridostigmine bromide may result in cholinergic crisis, a state characterized by increasing muscle weakness which, through involvement of the muscles of respiration, may lead to death. Myasthenic crisis due to an increase in the severity of the disease is also accompanied by extreme muscle weakness, and thus may be difficult to distinguish from cholinergic crisis on a symptomatic basis.

Such differentiation is extremely important, since increases in doses of pyridostigmine bromide or other drugs of this class in the presence of cholinergic crisis or of a refractory or “insensitive” state could have grave consequences. Osserman and Genkins 1 indicate that the differential diagnosis of the two types of crisis may require the use of Tensilon (edrophonium chloride) as well as clinical judgment. The treatment of the two conditions obviously differs radically.

Whereas the presence of myasthenic crisis suggests the need for more intensive anticholinesterase therapy, the diagnosis of cholinergic crisis, according to Osserman and Genkins 1 , calls for the prompt withdrawal of all drugs of this type. The immediate use of atropine in cholinergic crisis is also recommended. Atropine may also be used to abolish or obtund gastrointestinal side effects or other muscarinic reactions; but such use, by masking signs of overdosage, can lead to inadvertent induction of cholinergic crisis.

For detailed information on the management of patients with myasthenia gravis, the physician is referred to one of the excellent reviews such as those by Osserman and Genkins 2 , Grob 3 or Schwab. 4,5 Usage in Pregnancy: The safety of pyridostigmine bromide during pregnancy or lactation in humans has not been established. Therefore, use of pyridostigmine bromide in women who may become pregnant requires weighing the drug’s potential benefits against its possible hazards to mother and child.

🤒 Adverse Reactions 125 words ▾

ADVERSE REACTIONS: The side effects of pyridostigmine bromide are most commonly related to overdosage and generally are of two varieties, muscarinic and nicotinic. Among those in the former group are nausea, vomiting, diarrhea, abdominal cramps, increased peristalsis, increased salivation, increased bronchial secretions, miosis and diaphoresis. Nicotinic side effects are comprised chiefly of muscle cramps, fasciculation and weakness.

Muscarinic side effects can usually be counteracted by atropine, but for reasons shown in the preceding section the expedient is not without danger. As with any compound containing the bromide radical, a skin rash may be seen in an occasional patient. Such reactions usually subside promptly upon discontinuance of the medication.

To report SUSPECTED ADVERSE REACTIONS, contact Novadoz Pharmaceuticals LLC at 1-855-668-2369 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🧬 Clinical Pharmacology 55 words ▾

CLINICAL PHARMACOLOGY: Pyridostigmine bromide inhibits the destruction of acetylcholine by cholinesterase and thereby permits freer transmission of nerve impulses across the neuromuscular junction. Pyridostigmine is an analog of neostigmine (Prostigmin), but differs from it in certain clinically significant respects; for example, pyridostigmine is characterized by a longer duration of action and fewer gastrointestinal side effects.

📦 How Supplied / Storage and Handling 70 words ▾

HOW SUPPLIED: Pyridostigmine Bromide Oral Solution USP, 60 mg pyridostigmine bromide per teaspoonful (5 mL) is available as a clear, raspberry flavored solution and 0.23% w/w alcohol. It is supplied as follows: Bottles of 16 fluid ounces, (1 pint, 473 mL) NDC 72205-098-72 Store at 25°C (77°F); excursions permitted to 15° to 30°C (59°to 86°F). [see USP Controlled Room Temperature]. Dispense in tight, light-resistant containers as defined by the USP.

📋 Description 82 words ▾

DESCRIPTION: Pyridostigmine bromide oral solution, USP is an orally active cholinesterase inhibitor. Chemically, pyridostigmine bromide, USP is 3-hydroxy-1-methylpyridinium bromide dimethylcarbamate. Its structural formula is: The molecular formula of pyridostigmine bromide, USP is C 9 H 13 BrN 2 O 2 having a molecular weight of 261.12.

Pyridostigmine bromide oral solution, USP contains 60 mg pyridostigmine bromide per teaspoonful in a vehicle containing 0.23% w/w alcohol, glycerin, lactic acid, sodium benzoate, sorbitol, sucrose, raspberry-flavor (propylene glycol, Nat & Art flavor) and water. pyridostigmine-structure

⚠️ Precautions 46 words ▾

PRECAUTION: Pyridostigmine is mainly excreted unchanged by the kidney. 6,7,8 Therefore, lower doses may be required in patients with renal disease, and treatment should be based on titration of drug dosage to effect. 6,7 Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

📚 References 204 words ▾

REFERENCES: 1. Osserman KE, Genkins G. Studies in myasthenia gravis: Reduction in mortality rate after crisis.

JAMA. Jan 1963; 183:97-101. 2.

Osserman KE, Genkins G. Studies in myasthenia gravis. NY State J Med.

June 1961; 61:2076-2085. 3. Grob D.

Myasthenia gravis. A review of pathogenesis and treatment. Arch Intern Med.

Oct 1961; 108:615-638. 4. Schwab RS.

Management of myasthenia gravis. New Eng J Med. Mar 1963; 268:596-597.

5. Schwab RS. Management of myasthenia gravis.

New Eng J Med. Mar 1963; 268:717-719. 6.

Cronnelly R, Stanski DR, Miller RD, Sheiner LB. Pyridostigmine kinetics with and without renal function. Clin Pharmacol Ther.

1980; 28: No. 1, 78-81. 7.

Miller RD. Pharmacodynamics and pharmacokinetics of anticholinesterase. In: Ruegheimer E, Zindler M, ed.

Anesthesiology. (Hamburg, Germany: Congress; Sep 14-21, 1980; 222-223.) (Int Congr. No.

538), Amsterdam, Netherlands: Excerpta Medica; 1981. 8. Breyer-Pfaff U, Maier U, Brinkmann AM, Schumm F.

Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis. Clin Pharmacol Ther. 1985; 5:495-501.

The brands listed are trademarks or registered trademarks of their respective owners and are not affiliated with and do not endorse Novadoz Pharmaceuticals LLC. Manufactured by: MSN Pharmaceuticals Inc. Piscataway, NJ 08854 Distributed by: Novadoz Pharmaceuticals LLC Piscataway, NJ 08854 -3714 Issued on: 09/2023

📄 Package Label / Principal Display Panel 12 words ▾

PACKAGE LABEL PRINCIPAL DISPLAY PANEL 1 Pint (473 mL) Bottle Label pyridostigmine-bottle-label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
871
Units reimbursed last 4 qtrs
297K
Gross reimbursed last 4 qtrs
$270.4K
Avg / prescription
$310.47
Avg / unit
$0.9104
Latest quarter Q1 2026
283Rx
Medicaid pays / mL
$0.9104
gross reimbursed
vs
NADAC / mL
$0.7131
acquisition cost
=
Spread
+$0.1973
+28% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
34% FFS 66% MCO
Fee-for-service · 296 Rx Managed care · 575 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: 4,442 units · 44.3 per 100k residents MI New York: 48,931 units · 250 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 12,920 units · 103 per 100k residents IL Indiana: 9,672 units · 141 per 100k residents IN Ohio: no data reported OH Pennsylvania: 47,942 units · 370 per 100k residents PA New Jersey: 25,593 units · 275 per 100k residents NJ Massachusetts: 20,978 units · 300 per 100k residents MA California: 24,888 units · 63.9 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: 7,377 units · 84.6 per 100k residents VA Maryland: 10,760 units · 174 per 100k residents MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: 30,488 units · 281 per 100k residents NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 20,110 units · 65.9 per 100k residents TX Florida: 32,936 units · 146 per 100k residents FL
Units reimbursed · per 100k residents
44.3370
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Pennsylvania 370 /100k
2 Massachusetts 300 /100k
3 North Carolina 281 /100k
4 New Jersey 275 /100k
5 New York 250 /100k
6 Maryland 174 /100k
7 Florida 146 /100k
8 Indiana 141 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Pyridostigmine Bromide — the program that covers self-administered drugs. 9 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Pyridostigmine Bromide. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$5.53M
Claims incl. refills
71.4K
Beneficiaries
45.1K
Spend / beneficiary
$122.42
Spend / claim
$77.39
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Pyridostigmine Bromide — the ingredient across all brands.

Top reported reactions

Myasthenia Gravis1,283
Fatigue962
Asthenia779
Diarrhoea714
Dyspnoea659
Headache650
Nausea612

Age at onset

Neonate15
Infant8
Child20
Adolescent22
Adult787
Elderly760

Reporter sex

10,997 reports
Male · 40%
Female · 60%
Unknown · 0%

Serious outcomes

Hospitalization3,904
Death825
Life-threatening628
Disabling255
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 1,499 703
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.